(Total Views: 701)
Posted On: 11/26/2025 9:54:51 AM
Post# of 158771
Re: chazzledazzle #158663
Chazzledazzle posted the abstract for the presentation that Dr. Dolezal will be making at the upcoming San Antonio Breast Cancer Symposium. I noticed that Dr. H. S. Rugo, who is on our Scientific Advisory Board, is a co-author. She is division chief of breast medical oncology and a professor of medical oncology and therapeutics research at City of Hope. The City of Hope Orange County Lennar Foundation Cancer Center is 1 of the 6 study locations for the mTNBC trial. I found the protocol below on their website.
When I did a query for Leronlimab, this also turned up. I don’t remember seeing any written protocols previously where an institution was offering EAP.
I was curious to see what Dr. Dolezal’s experience was with Leronlimab. If you look at her bio at Stanford, her title is Clinical Associate Professor in the Division of Oncology. The only other affiliation shown is Genentech.
https://med.stanford.edu/profiles/milana-dolezal
Look back at an early record of the trial with carboplatin for mTNBC, however, and she is shown as a Sub-Investigator at Pacific Hematology Oncology.
https://clinicaltrials.gov/study/NCT03838367?...tions-card
I did some research with AI (which can be inaccurate) and it looks like she was practicing at Pacific Hematology before she joined Stanford. This is interesting because it shows her experience with Leronlimab. Also, Pacific Hematology in San Francisco is 1 of our 6 trial locations. She probably knows Dr. JL from her cancer work in San Francisco, which is also where Quest Clinical is located.
When I did a query for Leronlimab, this also turned up. I don’t remember seeing any written protocols previously where an institution was offering EAP.
I was curious to see what Dr. Dolezal’s experience was with Leronlimab. If you look at her bio at Stanford, her title is Clinical Associate Professor in the Division of Oncology. The only other affiliation shown is Genentech.
https://med.stanford.edu/profiles/milana-dolezal
Look back at an early record of the trial with carboplatin for mTNBC, however, and she is shown as a Sub-Investigator at Pacific Hematology Oncology.
https://clinicaltrials.gov/study/NCT03838367?...tions-card
I did some research with AI (which can be inaccurate) and it looks like she was practicing at Pacific Hematology before she joined Stanford. This is interesting because it shows her experience with Leronlimab. Also, Pacific Hematology in San Francisco is 1 of our 6 trial locations. She probably knows Dr. JL from her cancer work in San Francisco, which is also where Quest Clinical is located.
(19)
(0)
